APA

Solly F., Angelot F., Garand R., Ferrand C., Seillès E., Schillinger F., Decobecq A., Billot M., Larosa F., Plouvier E., Deconinck E., Legrand F., Saas P., Rohrlich P. & Garnache-Ottou F. (20120928). CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. : Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Chicago

Solly Françoise, Angelot Fanny, Garand Richard, Ferrand Christophe, Seillès Estelle, Schillinger Françoise, Decobecq Agnès, Billot Maryse, Larosa Fabrice, Plouvier Emmanuel, Deconinck Eric, Legrand Faezeh, Saas Philippe, Rohrlich Pierre-Simon and Garnache-Ottou Francine. 20120928. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. : Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Harvard

Solly F., Angelot F., Garand R., Ferrand C., Seillès E., Schillinger F., Decobecq A., Billot M., Larosa F., Plouvier E., Deconinck E., Legrand F., Saas P., Rohrlich P. and Garnache-Ottou F. (20120928). CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. : Cytometry. Part A : the journal of the International Society for Analytical Cytology.

MLA

Solly Françoise, Angelot Fanny, Garand Richard, Ferrand Christophe, Seillès Estelle, Schillinger Françoise, Decobecq Agnès, Billot Maryse, Larosa Fabrice, Plouvier Emmanuel, Deconinck Eric, Legrand Faezeh, Saas Philippe, Rohrlich Pierre-Simon and Garnache-Ottou Francine. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. : Cytometry. Part A : the journal of the International Society for Analytical Cytology. 20120928.